Skip to main content
NCBI home page
Annals of Surgery logoLink to Annals of Surgery
. 1995 Nov;222(5):646–653. doi: 10.1097/00000658-199511000-00007

Repeated administration of recombinant human insulin-like growth factor-I in patients after gastric surgery. Effect on metabolic and hormonal patterns.

C Goeters 1, N Mertes 1, J Tacke 1, U Bolder 1, M Kuhmann 1, P Lawin 1, D Löhlein 1
PMCID: PMC1234992  PMID: 7487212

Abstract

OBJECTIVE: The primary objective of this investigation was to evaluate the anticatabolic effects of repeated subcutaneous administration of recombinant human insulin-like growth factor-I (rhlGF-I) in patients after gastric surgery. SUMMARY BACKGROUND DATA: The anabolic and protein-sparing effects of growth hormone are primarily mediated by IGF-I. Malnutrition and catabolic states result in increasing blood levels of growth hormone and decreasing levels of IGF-I. Experimental data showed that exogenous IGF-I could attenuate or reverse catabolism. METHODS: After giving their written informed consent, 38 male and female patients undergoing gastrectomy (age 40-75 years, body mass index 17-30 kg/m2) were treated with 80 micrograms/kg body weight rhlGF-I or placebo in a prospective, randomized, double-blind study for 5 consecutive days. Patients received a standardized total parenteral nutritional regimen with 3 g/kg body weight glucose and 0.1 g/kg body weight nitrogen. Nitrogen balance and 3-methylhistidine excretion were measured daily. Hormone profiles (IGF-I, IGFBP1, IGFBP3, cortisol, insulin, glucagon, triiodothyronine [T3], levothyroxine [T4], and thyroxine-binding globulin) were taken.

Full text

PDF
646

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abribat T., Brazeau P., Davignon I., Garrel D. R. Insulin-like growth factor-I blood levels in severely burned patients: effects of time post injury, age of patient and severity of burn. Clin Endocrinol (Oxf) 1993 Nov;39(5):583–589. doi: 10.1111/j.1365-2265.1993.tb02413.x. [DOI] [PubMed] [Google Scholar]
  2. Baxter R. C., Hizuka N., Takano K., Holman S. R., Asakawa K. Responses of insulin-like growth factor binding protein-1 (IGFBP-1) and the IGFBP-3 complex to administration of insulin-like growth factor-I. Acta Endocrinol (Copenh) 1993 Feb;128(2):101–108. doi: 10.1530/acta.0.1280101. [DOI] [PubMed] [Google Scholar]
  3. Ceda G. P., Davis R. G., Rosenfeld R. G., Hoffman A. R. The growth hormone (GH)-releasing hormone (GHRH)-GH-somatomedin axis: evidence for rapid inhibition of GHRH-elicited GH release by insulin-like growth factors I and II. Endocrinology. 1987 Apr;120(4):1658–1662. doi: 10.1210/endo-120-4-1658. [DOI] [PubMed] [Google Scholar]
  4. Cioffi W. G., Gore D. C., Rue L. W., 3rd, Carrougher G., Guler H. P., McManus W. F., Pruitt B. A., Jr Insulin-like growth factor-1 lowers protein oxidation in patients with thermal injury. Ann Surg. 1994 Sep;220(3):310–319. doi: 10.1097/00000658-199409000-00007. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Clemmons D. R., Smith-Banks A., Underwood L. E. Reversal of diet-induced catabolism by infusion of recombinant insulin-like growth factor-I in humans. J Clin Endocrinol Metab. 1992 Jul;75(1):234–238. doi: 10.1210/jcem.75.1.1619015. [DOI] [PubMed] [Google Scholar]
  6. Dahn M. S., Lange M. P., Jacobs L. A. Insulinlike growth factor 1 production is inhibited in human sepsis. Arch Surg. 1988 Nov;123(11):1409–1414. doi: 10.1001/archsurg.1988.01400350123019. [DOI] [PubMed] [Google Scholar]
  7. Donahue S. P., Phillips L. S. Response of IGF-1 to nutritional support in malnourished hospital patients: a possible indicator of short-term changes in nutritional status. Am J Clin Nutr. 1989 Nov;50(5):962–969. doi: 10.1093/ajcn/50.5.962. [DOI] [PubMed] [Google Scholar]
  8. Grunfeld C., Sherman B. M., Cavalieri R. R. The acute effects of human growth hormone administration on thyroid function in normal men. J Clin Endocrinol Metab. 1988 Nov;67(5):1111–1114. doi: 10.1210/jcem-67-5-1111. [DOI] [PubMed] [Google Scholar]
  9. Guler H. P., Schmid C., Zapf J., Froesch E. R. Effects of recombinant insulin-like growth factor I on insulin secretion and renal function in normal human subjects. Proc Natl Acad Sci U S A. 1989 Apr;86(8):2868–2872. doi: 10.1073/pnas.86.8.2868. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Guler H. P., Zapf J., Scheiwiller E., Froesch E. R. Recombinant human insulin-like growth factor I stimulates growth and has distinct effects on organ size in hypophysectomized rats. Proc Natl Acad Sci U S A. 1988 Jul;85(13):4889–4893. doi: 10.1073/pnas.85.13.4889. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Herndon D. N., Barrow R. E., Kunkel K. R., Broemeling L., Rutan R. L. Effects of recombinant human growth hormone on donor-site healing in severely burned children. Ann Surg. 1990 Oct;212(4):424–431. doi: 10.1097/00000658-199010000-00005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Isaksson O. G., Lindahl A., Nilsson A., Isgaard J. Mechanism of the stimulatory effect of growth hormone on longitudinal bone growth. Endocr Rev. 1987 Nov;8(4):426–438. doi: 10.1210/edrv-8-4-426. [DOI] [PubMed] [Google Scholar]
  13. Jiang Z. M., He G. Z., Zhang S. Y., Wang X. R., Yang N. F., Zhu Y., Wilmore D. W. Low-dose growth hormone and hypocaloric nutrition attenuate the protein-catabolic response after major operation. Ann Surg. 1989 Oct;210(4):513–525. doi: 10.1097/00000658-198910000-00012. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Kimbrough T. D., Shernan S., Ziegler T. R., Scheltinga M., Wilmore D. W. Insulin-like growth factor-I response is comparable following intravenous and subcutaneous administration of growth hormone. J Surg Res. 1991 Dec;51(6):472–476. doi: 10.1016/0022-4804(91)90167-k. [DOI] [PubMed] [Google Scholar]
  15. Koea J. B., Douglas R. G., Breier B. H., Shaw J. H., Gluckman P. D. Synergistic effect of insulin-like growth factor-I administration on the protein-sparing effects of total parenteral nutrition in fasted lambs. Endocrinology. 1992 Aug;131(2):643–648. doi: 10.1210/endo.131.2.1639012. [DOI] [PubMed] [Google Scholar]
  16. Kupfer S. R., Underwood L. E., Baxter R. C., Clemmons D. R. Enhancement of the anabolic effects of growth hormone and insulin-like growth factor I by use of both agents simultaneously. J Clin Invest. 1993 Feb;91(2):391–396. doi: 10.1172/JCI116212. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Lieberman S. A., Butterfield G. E., Harrison D., Hoffman A. R. Anabolic effects of recombinant insulin-like growth factor-I in cachectic patients with the acquired immunodeficiency syndrome. J Clin Endocrinol Metab. 1994 Feb;78(2):404–410. doi: 10.1210/jcem.78.2.7508949. [DOI] [PubMed] [Google Scholar]
  18. Ross R. J., Miell J. P., Holly J. M., Maheshwari H., Norman M., Abdulla A. F., Buchanan C. R. Levels of GH binding activity, IGFBP-1, insulin, blood glucose and cortisol in intensive care patients. Clin Endocrinol (Oxf) 1991 Oct;35(4):361–367. doi: 10.1111/j.1365-2265.1991.tb03549.x. [DOI] [PubMed] [Google Scholar]
  19. Ross R., Miell J., Freeman E., Jones J., Matthews D., Preece M., Buchanan C. Critically ill patients have high basal growth hormone levels with attenuated oscillatory activity associated with low levels of insulin-like growth factor-I. Clin Endocrinol (Oxf) 1991 Jul;35(1):47–54. doi: 10.1111/j.1365-2265.1991.tb03495.x. [DOI] [PubMed] [Google Scholar]
  20. Shaw J. H., Wolfe R. R. An integrated analysis of glucose, fat, and protein metabolism in severely traumatized patients. Studies in the basal state and the response to total parenteral nutrition. Ann Surg. 1989 Jan;209(1):63–72. doi: 10.1097/00000658-198901000-00010. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Skottner A., Clark R. G., Fryklund L., Robinson I. C. Growth responses in a mutant dwarf rat to human growth hormone and recombinant human insulin-like growth factor I. Endocrinology. 1989 May;124(5):2519–2526. doi: 10.1210/endo-124-5-2519. [DOI] [PubMed] [Google Scholar]
  22. Ward M. W., Owens C. W., Rennie M. J. Nitrogen estimation in biological samples by use of chemiluminescence. Clin Chem. 1980 Aug;26(9):1336–1339. [PubMed] [Google Scholar]
  23. Young S. C., Clemmons D. R. Changes in insulin-like growth factor (IGF)-binding proteins after IGF-I injections in noninsulin-dependent diabetics. J Clin Endocrinol Metab. 1994 Mar;78(3):609–614. doi: 10.1210/jcem.78.3.7510305. [DOI] [PubMed] [Google Scholar]
  24. Ziegler T. R., Gatzen C., Wilmore D. W. Strategies for attenuating protein-catabolic responses in the critically ill. Annu Rev Med. 1994;45:459–480. doi: 10.1146/annurev.med.45.1.459. [DOI] [PubMed] [Google Scholar]
  25. Ziegler T. R., Young L. S., Ferrari-Baliviera E., Demling R. H., Wilmore D. W. Use of human growth hormone combined with nutritional support in a critical care unit. JPEN J Parenter Enteral Nutr. 1990 Nov-Dec;14(6):574–581. doi: 10.1177/0148607190014006574. [DOI] [PubMed] [Google Scholar]

Articles from Annals of Surgery are provided here courtesy of Lippincott, Williams, and Wilkins

RESOURCES